CD3 Antibody-Induced Dominant Self Tolerance in Overtly Diabetic NOD Mice

Journal of Immunology

Volumn 158, Issue 6, 1997, Pages 2947-2954

  Chatenoud, Lucienne ^a   Primo, Jacqueline ^a   Bach, Jean François ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN F(AB) FRAGMENT; MITOGENIC AGENT; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL; ARTICLE; BIOSYNTHESIS; FEMALE; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; REMISSION; SIGNAL TRANSDUCTION; SPLEEN; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MICE; MICE, INBRED NOD; MITOGENS; REMISSION INDUCTION; SELF TOLERANCE; SIGNAL TRANSDUCTION; SPLEEN; T-LYMPHOCYTES;

EID: 0031569177     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Castano, L., and G. S. Eisenbarth. 1990. Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu. Rev. Immunol. 8:647.
2. Bach, J. F. 1994. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr. Rev. 15:516.
3. Shizuru, J. A., C. Taylor-Edwards, B. A. Banks, A. K. Gregory and C. G. Fathman. 1988. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 240:659.
4. Kaufman, D. L., M. Clare-Salzler, J. Tian, T. Forsthuber, G. S. P. Ting, P. Robinson, M. A. Atkinson, E. E. Sercarz, A. J. Tobin, and P. V. Lehmann. 1993. Spontaneous loss of T cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366:69.
5. Zhang, Z. J., L. Davidson, G. Eisenbarth and H. L. Weiner. 1991. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. USA 88:10252.
6. Elias, D., and I. R. Cohen. 1994. Peptide therapy for diabetes in NOD mice. Lancet 343:704.
7. Tisch, R., X. D. Yang, S. M. Singer, R. S. Liblau, L. Fugger, and H. O. McDevitt. 1993. Immune response to glutamic acid decarboxylase correlates with insulitis in nonobese diabetic mice. Nature 366:72.
8. Leo, O., M. Foo, D. H. Sachs, L. E. Samelson and J. A. Bluestone. 1987. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA 84:1374.
9. Chatenoud, L., E. Thervet, J. Primo, and J. F. Bach. 1994. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 91:123.
10. Hirsch, R., R. E. Gress, D. H. Pluznik, M. Eckhaus, and J. A. Bluestone. 1989. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J. Immunol. 142:737.
11. Flamand, V., D. Abramowicz, M. Goldman, C. Biernaux, G. Huez, J. Urbain, M. Moser, and O. Leo. 1990. Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo. J. Immunol. 144:2875.
12. Ferran, C., K. Sheehan, M. Dy, R. Schreiber, S. Merite, P. Landais, L. H. Noel, G. Grau, J. Bluestone, J. F. Bach, and L. Chatenoud. 1990. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 20:509.
13. Alegre, M., P. Vandenabeele, V. Flamand, M. Moser, O. Leo, D. Abramowicz, J. Urbain, W. Fiers, and M. Goldman. 1990. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur. J. Immunol. 20:707.
14. Durez, P., D. Abramowicz, C. Gerard, M. Van Mechelen, Z. Amraoui, C. Dubois, O. Leo, T. Velu, and M. Goldman. 1993. In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J. Exp. Med. 177:551.
15. Yoshimoto, T., and W. E. Paul. 1994. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179:1285.
16. Boitard, C., R. Yasunami, M. Dardenne, and J. F. Bach. 1989. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J. Exp. Med. 169:1669.
17. + like thymocyte in the NOD mouse. Eur. J. Immunol. 26:2989.
18. Hirsch, R., M. Eckhaus, J. R. Auchincloss H, D. H. Sachs, and J. A. Bluestone. 1988. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J. Immunol. 140:3766.
19. + T cells. Transplantation 61:798.
20. 2 fragments-retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation 52:354.
21. Henrickson, M., J. Reid, J. S. Bellet, S. S. Sawchuk, and R. Hirsch. 1995. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11). Transplantation 60:828.
22. 2) anti-CD3 monoclonal antibody. Transplantation 60:1331.
23. 2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 49:1117.
24. Ferran, C., M. Dy, K. Sheehan, S. Merite, R. Schreiber, P. Landais, G. Grau, J. Bluestone, J. F. Bach, and L. Chatenoud. 1991. Inter-mouse strain differences in the in vivo anti-CD3-induced cytokine release. Clin. Exp. Immunol. 86:537.
25. Desilva, D. R., K. B. Urdahl, and M. K. Jenkins. 1991. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J. Immunol. 147:3261.
26. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16: 34.
27. Diaz-Gallo, C., M. Moscovitch-Lopatin, T. B. Strom, and V. R. Kelley. 1992. An anergic, islet-infiltrating T cell clone that suppresses murine diabetes secretes a factor that blocks interleukin 2/interleukin 4-dependent proliferation. Proc. Natl. Acad. Sci. USA 89:8656.
28. + beta islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 182:87.
29. Hayward, A. R., and M. Shreiber. 1989. Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes. J. Immunol. 143:1555.
30. Charlton, B., A. Bacelj, R. M. Slattery, and T. E. Mandel. 1989. Cyclophosphamide-induced diabetes in NOD/WEHI mice: evidence for suppression in spontaneous autoimmune diabetes mellitus. Diabetes 38:441.
31. Singer, S. M., R. Tisch, X. D. Yang, and H. O. McDevitt. 1993. An Abd transgene prevents diabetes in nonobese diabetic mice by inducing regulatory T cells. Proc. Natl. Acad. Sci. USA 90:9566.
32. g7 β-chain diminishes the spontaneous incidence of insulin-dependent diabetes mellitus. J. Immunol. 154:5567.
33. Shehadeh, N., F. Calcinaro, B. J. Bradley, I. Bruchlim, P. Vardi, and K. J. Lafferty. 1994. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 343:706.
34. Wicker, L. S., B. J. Miller, and Y. Mullen. 1986. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 35:855.
35. Dallman, M. J., O. Shiho, T. H. Page, K. J. Wood, and P. J. Morris. 1991. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J. Exp. Med. 173:79.
36. Rapoport, M. J., A. Jaramillo, D. Zipris, A. H. Lazarus, D. V. Serreze, E. H. Leiter, P. Cyopick, J. S. Danska, and T. L. Delovitch. 1993. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J. Exp. Med. 178:87.
37. Herold, K. C., J. A. Bluestone, A. G. Montag, A. Parihar, A. Wiegner, R. E. Gress, and R. Hirsch. 1992. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 41:385.
38. Hughes, C., J. A. Wolos, E. H. Giannini, and R. Hirsch. 1994. Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody. J. Immunol. 153:3319.
39. 2 fragments induce a selective T helper dysfunction. J. Immunol. 147:2088.
40. 2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J. Immunol. 154:5542.
41. Granelli-Piperno, A., M. Keane, and R. M. Steinman. 1988. Evidence that cyclosporine inhibits cell-mediated immunity primarily at the level of the T lymphocyte rather than the accessory cell. Transplantation 46:53S.
42. Granelli-Piperno, A., L. Andrus, and R. M. Steinman. 1986. Lymphokine and nonlymphokine mRNA levels in stimulated human T cells: kinetics, mitogen requirements, and effects of cyclosporin A. J. Exp. Med. 163:922.
43. Sigal, N. H., and F. J. Dumont. 1992. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu. Rev. Immunol. 10:519.
44. Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tuckerburden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, K. J. Winn, and T. C. Pearson. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:434.
45. Bach, J. F. 1993. Strategies in immunotherapy of insulin-dependent diabetes mellitus. Ann. NY Acad. Sci. 696:364.
46. Bolt, S., E. Routledge, I. Lloyd, L. Chatenoud, H. Pope, S. D. Gorman, M. Clark, and H. Waldmann. 1993. The generation of a humanized, nonmitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23:403.
47. Alegre, M. L., A. M. Collins, V. L. Pulito, R. A. Brosius, W. C. Olson, R. A. Zivin, R. Knowles, J. R. Thistlethwaite, L. K. Jolliffe, and J. A. Bluestone. 1992. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J. Immunol. 148:3461.